# US 8,465,756 B2 · Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,756 B2
- Document ID: US8465756B2
- Status: Granted
- Kind: B2
- Application number: 12/846,092
- Filed: 2010-07-29
- Published: 2011-02-17
- Granted: 2013-06-18
- Earliest claimed: 2009-08-12
- Assignees: National Health Research Institutes
- Applicants: Shih-Jen Liu; Hsin-Wei Chen; Pele Choi-Sing Chong; Chih-Hsiang Leng
- Inventors: Shih-Jen Liu; Hsin-Wei Chen; Pele Choi-Sing Chong; Chih-Hsiang Leng
- Web page: https://patentgrep.com/patent/US8465756B2

## CPC

- A61K 39/0011: {Cancer antigens}
- A61P 35/00: Antineoplastic agents
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An immunopeptide containing a T cell epitope from the tumor associated antigen L6 (TAL6) and a nucleic acid encoding the immunopeptide are described herein. The immunopeptide or its encoding nucleic acid can be used as a component of an immune composition for enhancing immune response against cancer cells that express TAL6.

## Claims

### Claim 1

An isolated immunopeptide, comprising the amino acid sequence of a T-cell epitope from the tumor associated antigen L6 (TAL6), wherein (i) the immunopeptide consists of the amino acid sequence of SEQ ID NO:2, or (ii) the T-cell epitope consists of the amino acid sequence of SEQ ID NO:4 and the immunopeptide has a maximum length of 50 amino acids.

### Claim 2 (depends on 1)

The isolated immunopeptide of claim 1, wherein the T-cell epitope is restricted to HLA-A2.

### Claim 3 (depends on 1)

The isolated immunopeptide of claim 1, further comprising an endoplasmic reticulum targeting sequence, wherein the T-cell epitope consists of the amino acid sequence of SEQ ID NO:4.

### Claim 4 (depends on 1)

The isolated immunopeptide of claim 1, further comprising a T helper-cell stimulating fragment having the amino acid sequence of QYIKANSKFIGITE (SEQ ID NO:24) or AKFVAAWTLK (SEQ ID NO:25), wherein the T-cell epitope consists of the amino acid sequence of SEQ ID NO:4.

### Claim 5 (depends on 1)

An immunogenic composition, comprising the immunopeptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 5)

The immunogenic composition of claim 5, further comprising an adjuvant.

### Claim 7 (depends on 1)

The isolated immunopeptide of claim 1, consisting of the amino acid sequence of SEQ ID NO:2.

### Claim 8 (depends on 1)

The isolated immunopeptide of claim 1, consisting of the amino acid sequence of SEQ ID NO:4.